CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 290 enrolled
Drug / intervention
2.5 mg Chlorhexidine gluconate chipdrug
Likely dose
2.5 mg Chlorhexidine gluconate chipfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02080403
NCT02080403Phase 3Completed

Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis.

Dexcel Pharma Technologies Ltd.·interventional·Posted Mar 6, 2014·Updated Sep 13, 2022

In Brief

A Phase 3 clinical trial evaluating 2.5 mg Chlorhexidine gluconate chip for Peri-Implantitis. Completed, enrolled 290 participants across 10 sites in 4 countries.

Detailed Summary

The objective of the study is to assess the efficacy and safety of PerioChip® (Chlorhexidine gluconate chip) in the treatment of patients with Peri-implantitis. The hypothesis of the study is that PerioChip® in adjunct to mechanical subgingival debridement is more effective in the treatment of peri-implantitis when compared to the common method of mechanical subgingival debridement alone. The primary efficacy measure will be the reduction in probing pocket depth at 6 months as measured at sites of qualifying target implant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Israel, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2018
Study CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.3 years ago

Interventions

2.5 mg Chlorhexidine gluconate chipdrug

Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.